Breaking News Instant updates and real-time market news.

ALXN

Alexion

$126.22

0.86 (0.69%)

13:37
06/27/19
06/27
13:37
06/27/19
13:37

FDA approves Alexion's Soliris for adult NMOSD patients

The U.S. Food and Drug Administration approved Soliris injection for intravenous use for the treatment of neuromyelitis optica spectrum disorder, or NMOSD, in adult patients who are anti-aquaporin-4 (AQP4) antibody positive. NMOSD is an autoimmune disease of the central nervous system that mainly affects the optic nerves and spinal cord, the FDA noted. The FDA granted the approval of Soliris to Alexion Pharmaceuticals. Soliris was first approved by the FDA in 2007. The drug is approved to reduce destruction of red blood cells in adults with a rare blood disease called paroxysmal nocturnal hemoglobinuria, for the treatment of adults and children with a rare disease that causes abnormal blood clots to form in small blood vessels in the kidneys, and for the treatment of adults with Myasthenia Gravis who are anti-acetylcholine receptor antibody positive.

  • 28

    Jun

  • 09

    Sep

ALXN Alexion
$126.22

0.86 (0.69%)

05/23/19
05/23/19
INITIATION
Target $173

Outperform
Alexion initiated with an Outperform at Wedbush
As previously reported, Wedbush analyst Laura Chico started Alexion with an Outperform rating and $173 price target, saying its launch of Utomiris "marks a new chapter" in the company's history amid its "conversion process" away from the flagship therapy Soliris. The analyst further contends that Ultomiris "raises the competitive bar" to offset the competition threat for Soliris, noting that the company's rich pipeline of 14 different programs and the attractive valuation add to her positive outlook on Alexion shares.
05/23/19
GSCO
05/23/19
DOWNGRADE
Target $142
GSCO
Neutral
Alexion assumed with a Neutral from Buy at Goldman Sachs
Goldman Sachs analyst Salveen Richter assumed coverage of Alexion Pharmaceuticals with a Neutral rating and $142 price target. The firm previously had a Buy rating on the shares. While the analyst sees pipeline optionality for the company, he notes a lack of definitive clinical data to date and emerging competition in gene therapy.
05/22/19
05/22/19
UPGRADE

Citi assumes coverage of large-cap biotech, upgrades Amgen and Gilead
Citi analyst Mohit Bansal assumed coverage of large-cap biotech stocks, assuming coverage with five Buy ratings -- Amgen (AMGN), Alexion Pharmaceuticals (ALXN), Vertex Pharmaceuticals (VRTX), Gilead Sciences (GILD), and BioMarin Pharmaceutical (BMRN) -- and two Neutral ratings -- Biogen (BIIB) and Regeneron Pharmaceuticals (REGN). Both Amgen and Gilead were upgraded to Buy from Neutral as part of the assumption of coverage. The analyst said he is "more optimistic" on the sector as a whole as he sees many biotechs going "back to basics" by investing in their internal pipelines and filling their pipelines with early stage assets. He suggests looking at large caps again, as many are returning to stability and growth. Bansal does not favor large M&A, suggesting discipline due to "realizing value with big M&As."
05/22/19
WEDB
05/22/19
INITIATION
Target $173
WEDB
Outperform
Alexion initiated with an Outperform at Wedbush
Wedbush analyst Laura Chico started Alexion with an Outperform rating and $173 price target.

TODAY'S FREE FLY STORIES

UAL

United Continental

$94.00

2.7 (2.96%)

16:18
07/16/19
07/16
16:18
07/16/19
16:18
Hot Stocks
Breaking Hot Stocks news story on United Continental »

United Continental…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jul

CCCL

China Ceramics

$0.87

(0.00%)

16:18
07/16/19
07/16
16:18
07/16/19
16:18
Hot Stocks
China Ceramics receives Nasdaq notification of non-compliance »

China Ceramics announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

UAL

United Continental

$94.00

2.7 (2.96%)

16:18
07/16/19
07/16
16:18
07/16/19
16:18
Hot Stocks
United Continental reports Q2 total passenger revenue up 6.1% y/y »

Consolidated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jul

UAL

United Continental

$94.00

2.7 (2.96%)

16:18
07/16/19
07/16
16:18
07/16/19
16:18
Earnings
United Continental reports Q2 adjusted EPS $4.21, consensus $4.08 »

Reports Q2 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jul

VNDA

Vanda Pharmaceuticals

$13.45

-0.13 (-0.96%)

16:18
07/16/19
07/16
16:18
07/16/19
16:18
Hot Stocks
Vanda Pharmaceuticals announces study results for tradipitant »

Vanda Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Aug

STIM

Neuronetics

$12.65

-0.2 (-1.56%)

, UNH

UnitedHealth

$264.60

-1.31 (-0.49%)

16:18
07/16/19
07/16
16:18
07/16/19
16:18
Recommendations
Neuronetics, UnitedHealth analyst commentary  »

UnitedHealth coverage…

STIM

Neuronetics

$12.65

-0.2 (-1.56%)

UNH

UnitedHealth

$264.60

-1.31 (-0.49%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jul

CTAS

Cintas

$239.46

-3.85 (-1.58%)

16:17
07/16/19
07/16
16:17
07/16/19
16:17
Earnings
Cintas sees FY20 EPS $8.30-$8.45, consensus $8.32 »

Sees FY20 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Jul

UAL

United Continental

$94.00

2.7 (2.96%)

16:17
07/16/19
07/16
16:17
07/16/19
16:17
Earnings
United Continental raises FY19 adj. EPS view to $10.50-$12.00, consensus $11.33 »

Prior view was…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jul

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

16:17
07/16/19
07/16
16:17
07/16/19
16:17
Technical Analysis
NASDAQ market internals summary »

Volume was average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CTAS

Cintas

$239.46

-3.85 (-1.58%)

16:16
07/16/19
07/16
16:16
07/16/19
16:16
Earnings
Cintas reports Q4 EPS ex-items $2.07, consensus $1.93 »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Jul

CSX

CSX

$79.57

1.05 (1.34%)

16:16
07/16/19
07/16
16:16
07/16/19
16:16
Hot Stocks
CSX says merchandise growth 'offset' intermodal weakness »

Chemicals increased as…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Jul

  • 26

    Aug

  • 13

    Nov

PETX

Aratana Therapeutics

$4.94

-0.11 (-2.18%)

16:16
07/16/19
07/16
16:16
07/16/19
16:16
Hot Stocks
Aratana Therapeutics shareholders vote to adopt merger with Elanco Animal Health »

Aratana Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

16:16
07/16/19
07/16
16:16
07/16/19
16:16
Technical Analysis
NYSE market internals summary »

Volume is above average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

UAL

United Continental

$94.00

2.7 (2.96%)

16:15
07/16/19
07/16
16:15
07/16/19
16:15
Earnings
United Continental reports Q2 adjusted EPS $4.21, consensus $4.08 »

Reports Q2 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jul

KSFTF

Kingsoft

$0.00

(0.00%)

16:15
07/16/19
07/16
16:15
07/16/19
16:15
Downgrade
Kingsoft rating change  »

Kingsoft downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CSX

CSX

$79.68

1.16 (1.48%)

16:13
07/16/19
07/16
16:13
07/16/19
16:13
Hot Stocks
CSX reports Q2 operating ratio fell to 57.4% since Q2 last year »

Last year's Q2…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Jul

  • 26

    Aug

  • 13

    Nov

PDD

Pinduoduo

$20.13

0.77 (3.98%)

16:12
07/16/19
07/16
16:12
07/16/19
16:12
Downgrade
Pinduoduo rating change  »

Pinduoduo downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NCBS

Nicolet Bankshares

$62.76

0.13 (0.21%)

16:12
07/16/19
07/16
16:12
07/16/19
16:12
Earnings
Nicolet Bankshares reports Q1 EPS $1.91 with items, consensus $1.09 »

During Q2, Nicolet sold…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WB

Weibo

$41.65

-1.39 (-3.23%)

16:12
07/16/19
07/16
16:12
07/16/19
16:12
Downgrade
Weibo rating change  »

Weibo downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CTRP

Ctrip

$36.88

-0.47 (-1.26%)

16:12
07/16/19
07/16
16:12
07/16/19
16:12
Upgrade
Ctrip rating change  »

Ctrip upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CSX

CSX

$79.67

1.15 (1.46%)

16:11
07/16/19
07/16
16:11
07/16/19
16:11
Hot Stocks
CSX falls 6% after reporting Q2 results below expectations »

CSX shares are trading at…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Jul

  • 26

    Aug

  • 13

    Nov

SENS

Senseonics

$1.68

-0.075 (-4.29%)

16:10
07/16/19
07/16
16:10
07/16/19
16:10
Syndicate
Senseonics announces $80M convertible senior notes offering »

Senseonics Holdings…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Sep

GALXF

Galaxy Resources

$0.00

(0.00%)

16:10
07/16/19
07/16
16:10
07/16/19
16:10
Downgrade
Galaxy Resources rating change  »

Galaxy Resources…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

INO

Inovio

$2.99

0.04 (1.36%)

16:09
07/16/19
07/16
16:09
07/16/19
16:09
Hot Stocks
Inovio to reduce annual burn rate by 25% and workforce by 28% »

Inovio Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SENS

Senseonics

$1.68

-0.075 (-4.29%)

16:08
07/16/19
07/16
16:08
07/16/19
16:08
Syndicate
Senseonics announces $25M common stock offering »

Senseonics Holdings…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Sep

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.